Analystreport

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $34.00 price target on

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report